Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histrelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.77 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | APLNR | P35414 | 5/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histrelin SCHEMBL7619565 | 1.00 | GNRHR (0.77) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL29405757 | 1.00 | GNRHR (0.77) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL84261 | 1.00 | GNRHR (0.76) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL29372688 | 0.99 | ABCC2 (0.78) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL5327685 | 0.99 | ABCC2 (0.78) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL18715 | 0.99 | ABCC2 (0.78) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL22288995 | 0.94 | GNRHR (0.67) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL1650282 | 0.94 | GNRHR (0.67) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 0.94 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL7751433 | 0.94 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15206 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| US-12595232-B2 | DRG-MDM2-1 for use as a novel Mouse Double Minute 2 (MDM2) inhibitor | BAHCESEHIR UNIVERSITESI (TR) | 2026-04-07 | — | — | US | claimed |
| EP-4713337-A1 | PRECISE LATE-STAGE MODIFICATION ON TRYPTOPHAN RESIDUE OF NATIVE PEPTIDES | University of Hong Kong Versitech Limited (HK) | 2026-03-25 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| WO-1994026207-A1 | METHODS AND FORMULATIONS FOR USE IN TREATING BENIGN GYNECOLOGICAL DISORDERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-11-24 | — | — | WO | claimed |
| US-5340584-A | Gonadotropin hormone releasing hormone, an estrogenic composition and a progestogen | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-08-23 | — | — | US | claimed |
| US-5340585-A | Administering slow release formulation of gonadotropin hormone releasing hormone and estrogen | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-08-23 | — | — | US | claimed |
| EP-0312052-B1 | Intranasal administration of polypeptides in powdered form | SYNTEX INC (US) | 1994-01-05 | — | — | EP | claimed |
| EP-0538443-A4 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | — | 1993-12-08 | — | — | EP | claimed |
| WO-1993015722-A1 | CONTROLLED DELIVERY OF PHARMACEUTICALS FROM PREFORMED POROUS MICROPARTICLES | SYNTEX (USA) INC. (US) | 1993-08-19 | — | — | WO | claimed |
| US-5211952-A | Drug delivery of gonadotropin hormone releasing hormones for time release | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-18 | — | — | US | claimed |
| EP-0538443-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. | UNIV SOUTHERN CALIFORNIA (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992018107-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0312052-A1 | Intranasal administration of polypeptides in powdered form | SYNTEX (U.S.A.) INC. (US) | 1989-04-19 | — | — | EP | claimed |